M. Awad

Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer

Shirin Khambata‐Ford, Christopher Harbison, Lowell L. Hart et al. · Journal of Clinical Oncology · 2010 · 268 citations · Full text

Medicine, Oncology, Pharmacology +17

Potential Predictive Markers of Benefit from Cetuximab in Metastatic Breast Cancer: An Analysis of Two Randomized Phase 2 Trials.

Lisa A. Carey, Joyce O’Shaughnessy, Joyce O’Shaughnessy et al. · Cancer Research · 2009 · 19 citations

Medicine, Oncology, Pharmacology +17

<i>K-Ras</i> mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: Retrospective analyses of the BMS099 trial

Shirin Khambata‐Ford, Christopher Harbison, Donald Woytowitz et al. · Journal of Clinical Oncology · 2009 · 19 citations

Medicine, Oncology, Pharmacology +17